“We are very pleased to work closely with OneWorld Health. Their expertise in drug development is a great match for ours in antigen design,” said A-CUBE’s Chief Executive, Nigel Fleming, PhD. "DNA vaccines can target multiple pathogens simultaneously, have persistent therapeutic effects, activate both T and B cell responses, do not need a cold chain, can be administered nasally and are inexpensive to produce -- something that is very important in developing countries. Finding the most suitable pathogen target protein is a critical bottleneck in vaccine design. We have a solution to this hurdle with our proprietary in silico Rational Vaccine Design Algorithm.”
“A-CUBE brings very innovative technology to vaccine design. We are excited to collaborate with them to develop new, affordable, and innovative vaccines for impoverished patients around the world,” said Richard Chin, MD and CEO of OWH.
A-CUBE, Inc., is a venture capital backed company (funded by JAIC and yet2Ventures.com)
Headquartered in South San Francisco, OneWorld Health is a non-profit research and development organization that discovers, develops and delivers safe, effective and affordable new treatments and interventions for impoverished patients, especially children, suffering from neglected diseases in the developing world. More information can be found here: www.oneworldhealth.org.
# # #
The mission of the Institute for One World Health is to develop safe, effective and affordable new medicines for people with infectious diseases in the developing world. More information can be found at www.oneworldhealth.org.